Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02916420 | Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma | unknown | Phase 3 | 73 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01653067 | STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma(STORM) | unknown | Phase 2 | 88 | Mathias Witzens-HarigOTHER | 1 | Oct 27, 2016 |
| clinicaltrials |
| NCT02819583 | CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Oct 25, 2016 | clinicaltrials |
| NCT02934204 | Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma | unknown | Phase 2 | 51 | Guangdong Provincial People's HospitalOTHER | 1 | Oct 14, 2016 | clinicaltrials |
| NCT02927717 | An Italian Experience on Grade 3b Follicular Lymphoma(FL3b-Oss-2015) | unknown | — | 60 | A.O.U. Città della Salute e della ScienzaOTHER | 0 | Oct 7, 2016 | clinicaltrials |
| NCT02457650 | T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT02851589 | Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 1, 2016 | clinicaltrials |
| NCT01279902 | Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL | unknown | Phase 2 | 32 | Asan Medical CenterOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT02184897 | Pharmacokinetic and Pharmacodynamic Study of Lenograstim for Hematopoietic Stem Cell Mobilization | unknown | N/A | 24 | Asan Medical CenterOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT02842931 | R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis | unknown | Phase 3 | 300 | National Research Center for Hematology, RussiaNETWORK | 1 | Jul 25, 2016 | clinicaltrials |
| NCT01671826 | Autologous Stem Cell Transplantation for Myeloma Patients Over 65 Years(LATMM) | unknown | — | 55 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 24, 2016 | clinicaltrials |
| NCT02779101 | Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL) | unknown | Phase 2 | 21 | Prof. Dr. Matthias PreusserOTHER | 1 | Jun 22, 2016 | clinicaltrials |
| NCT02797041 | Bortezomib as First Salvage Therapy for Myeloma Patients Previously Exposed to Bortezomib as Initial Treatment.(REBOUND) | unknown | — | 100 | IRCCS Centro di Riferimento Oncologico della BasilicataOTHER | 0 | Jun 14, 2016 | clinicaltrials |
| NCT02792491 | Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over | unknown | Phase 2 | 57 | Pusan National University HospitalOTHER | 0 | Jun 9, 2016 | clinicaltrials |
| NCT02777736 | CNS Prophylaxis in Diffuse Large B-cell Lymphoma(CLSG-CNS-001) | unknown | Phase 3 | 500 | Czech Lymphoma Study GroupOTHER | 1 | Jun 6, 2016 | clinicaltrials |
| NCT02791217 | Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool | unknown | — | 100 | Assuta Medical CenterOTHER | 0 | Jun 6, 2016 | clinicaltrials |
| NCT01522872 | Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 98 | Threshold PharmaceuticalsINDUSTRY | 1 | Jun 2, 2016 | clinicaltrials |
| NCT01933711 | Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma | unknown | Phase 3 | 328 | University Hospital HeidelbergOTHER | 1 | May 13, 2016 | clinicaltrials |
| NCT02758925 | CyBeR Association in Relapsed/Refractory DLBCL(CyBeR-Lymph) | unknown | Phase 2 | 78 | University Hospital, CaenOTHER | 0 | May 4, 2016 | clinicaltrials |
| NCT02753062 | Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma(PTLD) | unknown | Phase 2 | 22 | Asan Medical CenterOTHER | 1 | Apr 27, 2016 | clinicaltrials |
| NCT02362165 | CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma | unknown | Phase 3 | 236 | Sun Yat-sen UniversityOTHER | 1 | Apr 20, 2016 | clinicaltrials |
| NCT02507479 | Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies | unknown | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Apr 20, 2016 | clinicaltrials |
| NCT02240537 | Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer(BBMPI03) | unknown | Phase 1 | 4 | Benovus Bio, Inc.INDUSTRY | 1 | Apr 19, 2016 | clinicaltrials |
| NCT02388581 | First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCL | unknown | Phase 2 | 30 | National Health Research Institutes, TaiwanOTHER | 1 | Mar 25, 2016 | clinicaltrials |
| NCT01541332 | Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 70 | OncotherapeuticsINDUSTRY | 1 | Mar 10, 2016 | clinicaltrials |
| NCT01864889 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19(CART19) | unknown | N/A | 12 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT01886976 | Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138(CART-138) | unknown | Phase 1 / Phase 2 | 10 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT01949818 | Treatment of Diffuse Large B Cell Lymphoma | unknown | Phase 4 | 120 | Mingzhi ZhangOTHER | 1 | Dec 30, 2015 | clinicaltrials |
| NCT02438501 | Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma(WUCC-NHL02) | unknown | Phase 3 | 166 | Di DengOTHER | 1 | Dec 14, 2015 | clinicaltrials |
| NCT02449252 | Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Follicular Lymphoma | unknown | Phase 3 | 120 | Wuhan UniversityOTHER | 1 | Dec 14, 2015 | clinicaltrials |
| NCT02449265 | Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma | unknown | Phase 3 | 160 | Wuhan UniversityOTHER | 1 | Dec 14, 2015 | clinicaltrials |
| NCT02449278 | The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma | unknown | Phase 3 | 120 | Wuhan UniversityOTHER | 1 | Dec 14, 2015 | clinicaltrials |
| NCT01793844 | A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients | unknown | — | 732 | Sun Yat-sen UniversityOTHER | 1 | Dec 11, 2015 | clinicaltrials |
| NCT02109861 | Microdose Study of Melphalan, Bortezomib and Dexamethasone(Phase-0-MM) | unknown | Early Phase 1 | 6 | Henrik GregersenOTHER | 1 | Dec 8, 2015 | clinicaltrials |
| NCT02624440 | Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple Myeloma(SUTRICA) | unknown | Phase 2 | 300 | Henrik GregersenOTHER | 1 | Dec 8, 2015 | clinicaltrials |
| NCT01735604 | Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy | unknown | Phase 1 / Phase 2 | 50 | Chinese PLA General HospitalOTHER | 1 | Sep 29, 2015 | clinicaltrials |
| NCT02531841 | High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma(MATRix) | unknown | Phase 3 | 250 | University Hospital FreiburgOTHER | 1 | Aug 25, 2015 | clinicaltrials |
| NCT01812096 | Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China(MM) | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 18, 2015 | clinicaltrials |
| NCT00800059 | Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma(TMI-ASCT) | unknown | Phase 1 / Phase 2 | 27 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 27, 2015 | clinicaltrials |
| NCT01960192 | Treatment of Primary CNS Lymphoma(FVD) | unknown | Phase 4 | 50 | Mingzhi ZhangOTHER | 1 | Jul 21, 2015 | clinicaltrials |
| NCT02145715 | Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma(MUKsix) | unknown | Phase 1 / Phase 2 | 54 | Prof Jamie CavenaghOTHER | 1 | Jun 26, 2015 | clinicaltrials |
| NCT02467647 | The Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy(HLJDT-2016) | unknown | Phase 1 | 500 | Wuhan UniversityOTHER | 1 | Jun 10, 2015 | clinicaltrials |
| NCT02456207 | A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma | unknown | Phase 2 | 80 | Sinocelltech Ltd.INDUSTRY | 1 | May 28, 2015 | clinicaltrials |
| NCT02423837 | Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma(BRiF) | unknown | Phase 3 | 200 | National Research Center for Hematology, RussiaNETWORK | 1 | Apr 22, 2015 | clinicaltrials |
| NCT02399189 | MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma | unknown | Phase 2 | 39 | Jun ZhuOTHER | 1 | Apr 13, 2015 | clinicaltrials |
| NCT02336386 | CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma | unknown | Phase 3 | 100 | Beijing Chao Yang HospitalOTHER | 1 | Jan 13, 2015 | clinicaltrials |
| NCT02093910 | Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy | unknown | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Nov 19, 2014 | clinicaltrials |
| NCT02270307 | MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis(MSC-CY) | unknown | Phase 2 / Phase 3 | 40 | National Research Center for Hematology, RussiaNETWORK | 1 | Oct 21, 2014 | clinicaltrials |
| NCT02267590 | Tissue Collection for Biomarkers Determining Resistance to Ibrutinib(CLARITY) | unknown | — | 120 | Royal Marsden NHS Foundation TrustOTHER | 1 | Oct 17, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Nov 2, 2016source: clinicaltrials